<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332916</url>
  </required_header>
  <id_info>
    <org_study_id>CANMEM</org_study_id>
    <nct_id>NCT01332916</nct_id>
  </id_info>
  <brief_title>Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging</brief_title>
  <acronym>CANMEM</acronym>
  <official_title>Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate memory problems in patients with cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of patient&#xD;
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the relationship between memory impairment and brain dysfunction</measure>
    <time_frame>Before chemotherapy (baseline), end of chemotherapy and follow-up up to 12 months after chemotherapy</time_frame>
    <description>The main objective is to assess the relationship between memory impairment and brain dysfunction in patients treated with adjuvant chemotherapy for breast cancer (before and after treatment), compared to a group of healthy subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of age</measure>
    <time_frame>Before chemotherapy (baseline), end of chemotherapy and follow-up up to 12 months after chemotherapy</time_frame>
    <description>The secondary objective is to assess the impact of age on the extent of memory impairment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>patients aged 45 and over group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients aged 45 and over with breast cancer and should receive an adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers (controls) aged 45 and over</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy volunteers (controls) aged 45 and over</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cognitive tests and cerebral IRM</intervention_name>
    <description>cognitive tests and cerebral IRM</description>
    <arm_group_label>patients aged 45 and over group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cognitive tests and cerebral IRM</intervention_name>
    <description>cognitive tests and cerebral IRM</description>
    <arm_group_label>healthy volunteers (controls) aged 45 and over</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for patients:&#xD;
&#xD;
          -  Patients aged 45 and over&#xD;
&#xD;
          -  Patients from Grade 3 'end of primary schooling &quot;minimum (scale Barbizet)&#xD;
&#xD;
          -  Non-Metastatic Breast Cancer&#xD;
&#xD;
          -  Adjuvant Chemotherapy: FEC, including Docetaxel Protocols&#xD;
&#xD;
          -  No major cognitive impairment&#xD;
&#xD;
          -  No previous neurological&#xD;
&#xD;
          -  Lack of personality disorders and psychiatric disorders evolutionary&#xD;
&#xD;
          -  Having signed the informed consent of study participation&#xD;
&#xD;
        Inclusion Criteria for control group:&#xD;
&#xD;
          -  Women from the general population aged 45 and over, and matched in age and cultural&#xD;
             level in patients&#xD;
&#xD;
          -  Topics of Grade 3 'end of primary schooling &quot;minimum (scale Barbizet)&#xD;
&#xD;
          -  No prior cancer&#xD;
&#xD;
          -  No major cognitive impairment&#xD;
&#xD;
          -  No previous neurological&#xD;
&#xD;
          -  Lack of personality disorders and psychiatric disorders evolutionary&#xD;
&#xD;
          -  Participating in the IMAP Protocol No. ID-BCR: 2007-A00414-49 or IMAP+(n° ID RCB&#xD;
             2011-A01493-38)(see how the study below) have signed forms no objection and consent to&#xD;
             study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Traduction (français &gt; anglais)&#xD;
&#xD;
          -  Metastatic&#xD;
&#xD;
          -  Cancer of the breast other than primitive&#xD;
&#xD;
          -  Patients with paraneoplastic syndrome&#xD;
&#xD;
          -  Patients under 45 years&#xD;
&#xD;
          -  Patients whose achievement is below level 3 'end of primary schooling &quot;(scale&#xD;
             Barbizet)&#xD;
&#xD;
          -  Patients with adjuvant chemotherapy is associated with targeted therapy&#xD;
&#xD;
          -  Patients who have received other cancer treatments (chemotherapy or radiotherapy&#xD;
             brain)&#xD;
&#xD;
          -  Contraindication to the implementation of an MRI (claustrophobia, metal objects in the&#xD;
             body)&#xD;
&#xD;
          -  disorders of higher functions existing in the administration of chemotherapy&#xD;
&#xD;
          -  Neurologic earlier&#xD;
&#xD;
          -  Pathology psychiatric evolutionary&#xD;
&#xD;
          -  Refusal of participation&#xD;
&#xD;
          -  Patients unable to meet the cognitive tests&#xD;
&#xD;
          -  Drug use&#xD;
&#xD;
          -  Heavy drinking&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre de recherche CYCERON</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François BACLESSE</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>April 8, 2011</study_first_submitted>
  <study_first_submitted_qc>April 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>April 24, 2014</last_update_submitted>
  <last_update_submitted_qc>April 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2014</last_update_posted>
  <responsible_party>
    <name_title>Pr Florence JOLY-LOBBEDEZ</name_title>
    <organization>Centre François Baclesse</organization>
  </responsible_party>
  <keyword>No metastatic breast cancer</keyword>
  <keyword>cognitive troubles</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

